Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Farriols

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 23, 2024
Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case exampleHéctor Carlos García-Díaz, Simeon Eremiev, Javier Gómez-Alonso, et al.
Scientific Reports|February 22, 2020
An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disordersMar Riveiro-Barciela, Paula Gubern, Luisa Roade, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 28, 2025
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genesHéctor Carlos García-Díaz, María Larrosa-Garcia, Javier Gómez-Alonso, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|June 28, 2025
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genesHéctor Carlos García-Díaz, María Larrosa-Garcia, Javier Gómez-Alonso, et al.
Current Oncology (Toronto, Ont.)|September 27, 2023
Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort StudyMaria-Josep Carreras, Elena Tomás-Guillén, Anna Farriols, et al.
Frontiers in Medicine|August 1, 2022
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening RateLaia Aceituno, Juan Bañares, Lourdes Ruiz-Ortega, et al.
Frontiers in Medicine|September 8, 2022
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practiceMònica Sabaté Gallego, Eulàlia Pérez Esquirol, Núria Garcia Doladé, et al.
Journal of Chemotherapy (Florence, Italy)|March 10, 2026
Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitalsHéctor Carlos García-Díaz, Javier Gómez-Alonso, María Teresa Rabuñal-Álvarez, et al.
Pharmaceutics|December 31, 2025
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell TherapyJavier Varela-González-Aller, Mario Andrés Sánchez-Salinas, Iñaki Troconiz, et al.
Cancers|April 27, 2024
Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid TumorsMaria-Josep Carreras, Berta Renedo-Miró, Carolina Valdivia, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 23, 2024
Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case exampleHéctor Carlos García-Díaz, Simeon Eremiev, Javier Gómez-Alonso, et al.
Scientific Reports|February 22, 2020
An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disordersMar Riveiro-Barciela, Paula Gubern, Luisa Roade, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 28, 2025
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genesHéctor Carlos García-Díaz, María Larrosa-Garcia, Javier Gómez-Alonso, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|June 28, 2025
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genesHéctor Carlos García-Díaz, María Larrosa-Garcia, Javier Gómez-Alonso, et al.
Current Oncology (Toronto, Ont.)|September 27, 2023
Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort StudyMaria-Josep Carreras, Elena Tomás-Guillén, Anna Farriols, et al.
Frontiers in Medicine|August 1, 2022
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening RateLaia Aceituno, Juan Bañares, Lourdes Ruiz-Ortega, et al.
Frontiers in Medicine|September 8, 2022
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practiceMònica Sabaté Gallego, Eulàlia Pérez Esquirol, Núria Garcia Doladé, et al.
Journal of Chemotherapy (Florence, Italy)|March 10, 2026
Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitalsHéctor Carlos García-Díaz, Javier Gómez-Alonso, María Teresa Rabuñal-Álvarez, et al.
Pharmaceutics|December 31, 2025
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell TherapyJavier Varela-González-Aller, Mario Andrés Sánchez-Salinas, Iñaki Troconiz, et al.
Cancers|April 27, 2024
Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid TumorsMaria-Josep Carreras, Berta Renedo-Miró, Carolina Valdivia, et al.
Pageof 2